Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.
Sign up now!
This section covers the role of Factor Xa in coagulation, and discusses the use of direct and indirect Factor Xa inhibitors as anticoagulants
|Prevention of VTE in patients undergoing elective hip or knee replacement surgery||✓||✓||✓
|Treatment of DVT and PE and prevention of recurrent DVT and PE||✓a||✓a||✓|
|Prevention of stroke and systemic embolism in patients with NVAF with ≥1 risk factors||✓||✓||✓|
|Secondary prevention of ACS||✓b||x||x|
|Prevention of atherothrombotic events in adult patients with CAD or symptomatic PAD at high risk of ischaemic eventsc||✓||x||x|
aCan be used without pre-treatment with parenteral anticoagulant; bIn patients with elevated cardiac biomarkers and no prior stroke or TIA, and co-administered with ASA or ASA plus clopidogrel or ticlopidine; cco-administered with ASA